Transplant immunology最新文献

{"title":"Ezetimibe pretreatment attenuates early ischemia-reperfusion injury in a rat model of lung transplantation.","authors":"Ha Eun Kim, Soo Han Bae, Seokjin Haam, Song Yee Kim, Moo Suk Park, Jin Gu Lee","doi":"10.1016/j.trim.2026.102464","DOIUrl":"https://doi.org/10.1016/j.trim.2026.102464","url":null,"abstract":"<p><p>Ischemia-reperfusion injury (IRI) after transplantation causes early and late graft dysfunction. Ezetimibe (Eze) is a lipid-reducing agent that has been reported to attenuate oxidative stress and inflammation in non-pulmonary models of ischemia-reperfusion. We examined its effect in a rat lung transplantation model. Lewis rats (n = 8/group) underwent left lung transplantation without pretreatment (LT) or with Eze pretreatment of the donor (LT-D), recipient (LT-R), or both (LT-DR). Eze (1 mg/kg) was given orally three times weekly for 2 weeks, and donor lungs were transplanted after 6 h of cold storage. Graft gas exchange, histology, inflammation, and apoptosis were assessed after 2 h of reperfusion. Graft PaO2/FiO2, measured with the contralateral hilum clamped, differed among the groups (176.8 ± 149.6, 265.1 ± 124.3, 321.9 ± 130.2, and 412.6 ± 142.3 mmHg in LT, LT-D, LT-R, and LT-DR; p = 0.015) and was significantly higher than in LT only in LT-DR. All treatment groups had lower lung injury scores than LT (16.62 ± 0.65 vs 12.25 ± 0.78, 10.95 ± 0.46, and 10.72 ± 0.40; p < 0.001). Plasma inflammatory cytokines and lung tissue myeloperoxidase were also lower in the treatment groups, and TUNEL positivity was significantly lower only in LT-DR. In conclusion, Eze pretreatment attenuated early IRI in a rat model of lung transplantation. Because the AMPK/Nrf2 pathway and direct indices of oxidative stress were not measured, the mechanism of this protection remains undetermined, and the findings are confined to the first 2 h after reperfusion.</p>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":" ","pages":"102464"},"PeriodicalIF":1.6,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy after renal transplant: Truth or dare? A retrospective analysis from a tertiary care centre in India.","authors":"Yashendu Sarda, Harshita Sharma, Manas R Behera, Mandakini Pradhan, Apurwa Pratap Mall, Narayan Prasad, Manas R Patel, Jeyakumar Meyyappan, Ravi S Kushwaha, Monika Yachha, Anupma Kaul","doi":"10.1016/j.trim.2026.102463","DOIUrl":"https://doi.org/10.1016/j.trim.2026.102463","url":null,"abstract":"<p><strong>Introduction: </strong>Women with end-stage kidney disease (ESKD) often face fertility challenges due to hypothalamic-pituitary-gonadal axis disruption. While pregnancy is rare during dialysis, kidney transplantation restores fertility potential, albeit with increased maternal and foetal risks. This study evaluates maternal and foetal outcomes in post-renal transplant pregnancies at a tertiary care centre.</p><p><strong>Methodology: </strong>A retrospective study was conducted at our hospital on female renal transplant recipients between January 2010 and January 2024. All patients who conceived post-transplant were included. Clinical data were extracted from hospital electronic medical records, including transplant details, immunosuppression, antenatal course, and pregnancy outcomes.</p><p><strong>Results: </strong>Out of 215 female transplant recipients, 11 conceived post-transplant (5.1%). Among them, 9 pregnancies resulted in live births, 1 in stillbirth, and 1 ended in abortion. Mean age at pregnancy was 28.6 ± 1.74 years. All patients underwent ABO-compatible transplantation. Induction therapy included ATG (54.5%), basiliximab (27.3%), or none (18.2%). All patients were maintained on triple immunosuppression with tacrolimus, prednisone (≤10 mg/day), and azathioprine. Complications included maternal viz. gestational hypertension, pre-eclampsia, preterm delivery, and fetal viz. stillbirth and fetal growth restriction (FGR). Fetal outcomes included 81.8% live births, 9.1% intrauterine death, and 9.1% abortion. Graft outcomes showed stable function in 45.5%, dysfunction in 54.5%, and graft loss in 36.3%.</p><p><strong>Conclusion: </strong>Pregnancy after kidney transplantation is feasible and frequently successful, though associated with maternal and foetal complications. Meticulous multidisciplinary care and regular monitoring are essential to optimize outcomes and preserve graft function.</p>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":" ","pages":"102463"},"PeriodicalIF":1.6,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149208066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging stem cell strategies for neurodegenerative diseases.","authors":"Marhaen Hardjo, Alfi Sophian","doi":"10.1016/j.trim.2026.102465","DOIUrl":"10.1016/j.trim.2026.102465","url":null,"abstract":"<p><p>Degenerative diseases continue to impose a substantial global health burden with limited curative options. Neurodegenerative diseases, the principal focus of this review, are among the largest contributors to this burden. Stem cell therapies have emerged as a promising approach, offering the potential to replace lost cells, modulate pathological microenvironments, and restore tissue function through both direct cell replacement and paracrine mechanisms. However, conventional stem cell strategies encounter persistent obstacles including immune rejection, tumorigenicity, poor engraftment, and limited long-term efficacy in chronic disease settings. This narrative review synthesizes recent and emerging innovations in stem cell therapy for neurodegenerative diseases across four major domains: (i) emerging mechanisms of stem cell action, including activation of dormant neural stem cells (NSCs), exosome-based cell-free therapies, and rejuvenation of aged stem cells; (ii) emerging cell types such as pre-morula stem cells (PMSCs), perinatal stem cells, SSEA-4+ human umbilical cord mesenchymal stem cells (hUC-MSCs), and iPSC-derived mesenchymal progenitor cells (MiMPCs); (iii) advanced delivery platforms including three-dimensional (3D) biomaterial scaffolds, injectable hydrogels, and stem cell membrane-coated nanoparticles (CMNPs); and (iv) gene-editing strategies, particularly CRISPR/Cas9-mediated generation of hypoimmunogenic induced pluripotent stem cell (iPSC) lines for allogeneic, off-the-shelf cell therapies. Key translational gaps, including standardization of exosome isolation and scaffold fabrication protocols, long-term safety and immunogenicity assessment, and ethical and regulatory frameworks, are critically evaluated, and future research directions are proposed. In addition, the review states the level of evidence (in vitro, animal, or human) supporting each approach and summarizes their clinical status in a single table. Addressing these challenges through interdisciplinary collaboration will be essential to realizing the full potential of stem cell-based regenerative medicine for degenerative diseases.</p>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":" ","pages":"102465"},"PeriodicalIF":1.6,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gelatinous transformation and concomitant fibrosis of bone marrow in a patient with relapsed myelodysplastic syndrome following unrelated bone marrow transplantation","authors":"Naonori Harada,&nbsp;Makoto Nishijima,&nbsp;Yuto Izuta,&nbsp;Kumiyo Tazoe,&nbsp;Yusuke Kizawa,&nbsp;Hiroshi Shiragami,&nbsp;Nobuhiko Ohnishi,&nbsp;Naoki Hosaka","doi":"10.1016/j.trim.2026.102448","DOIUrl":"10.1016/j.trim.2026.102448","url":null,"abstract":"<div><div>Gelatinous transformation of bone marrow (GTBM) is a rare histological condition characterized by deposition of hyaluronic acid–rich gelatinous material, usually accompanied by adipocyte atrophy, reduced reticulin fibers, and hypocellularity. Although most frequently associated with malnutrition and severe weight loss, GTBM has also been reported in hematological malignancies. The coexistence of GTBM and bone marrow fibrosis is rarely described, and its underlying mechanisms remain unclear.</div><div>We report a 69-year-old woman with myelodysplastic syndrome with excess blasts-1 (MDS-EB-1) harboring a complex karyotype including chromosome 7 abnormalities, classified as very high risk by IPSS-R. She underwent unrelated bone marrow transplantation and achieved complete remission. On day 35, she developed acute skin graft-versus-host disease (GVHD), which resolved with immunosuppressive therapy. Five months later, she presented with pancytopenia, chronic cutaneous GVHD, severe anorexia, 15-kg weight loss, and malnutrition (BMI 11.5 kg/m²). Bone marrow aspiration yielded a dry tap, while biopsy revealed Alcian blue–positive gelatinous material, reticulin fibrosis, and preserved adipocytes. Her disease progressed to acute myeloid leukemia with 50% circulating blasts and was refractory to azacitidine and CPX-351, leading to death from progression.</div><div>This case illustrates that GTBM and marrow fibrosis can occur simultaneously in relapsed MDS after transplantation, potentially driven by cytokine dysregulation related to neoplastic clones and chronic GVHD.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"98 ","pages":"Article 102448"},"PeriodicalIF":1.6,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148778021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of ABO incompatibility on adult deceased donor liver transplantation outcomes: A 20-year retrospective study using the SRTR database","authors":"Sukhdeep Jatana,&nbsp;Kevin Verhoeff,&nbsp;Zofia Czarnecka,&nbsp;A.M. James Shapiro,&nbsp;Khaled Dajani,&nbsp;Blaire Anderson,&nbsp;David L. Bigam","doi":"10.1016/j.trim.2026.102444","DOIUrl":"10.1016/j.trim.2026.102444","url":null,"abstract":"<div><h3>Background</h3><div>ABO-incompatible (ABOi) deceased donor liver transplantation (DDLT) is seldom used due to concerns regarding postoperative outcomes, derived from predominantly older cohorts with small sample sizes. The aim of this study is to assess the impact of ABO incompatibility on outcomes of DDLT in a large, contemporary cohort.</div></div><div><h3>Methods</h3><div>Adult DDLT patients were included from the Scientific Registry of Transplant Recipients (SRTR) database who underwent transplant from 2004 to 2024. Demographics and complications were compared between ABOi and ABO-compatible (ABO-c) cohorts. Multivariate Cox proportional hazards models were generated to assess the impact of ABO incompatibility on 5-year outcomes.</div></div><div><h3>Results</h3><div>A total of 125,997 patients were included, with 1371 (1.1%) being ABOi. The ABOi cohort tended to be younger (53.0 ± 11.9vs54.5 ± 11.0,<em>p</em> &lt; 0.001) but with severe disease requiring preoperative ICU care (24.4%vs14.1%,<em>p</em> &lt; 0.001) and with higher MELD scores (25.6vs21.9,<em>p</em> &lt; 0.001). Multivariate survival modelling showed that ABOi is not associated with graft loss (defined as mortality or retransplant; aHR 1.00, 95%CI 0.84–1.18) or mortality (aHR 0.83, 95%CI 0.68–1.01), but with increased likelihood of retransplant (aHR 2.08, 95%CI 1.42–3.06). Results were similar when A2 to O incompatible transplants were excluded.</div></div><div><h3>Conclusions</h3><div>ABOi DDLT is associated with increased likelihood of retransplant but did not show an association with mortality, supporting its use in highly selective unwell patients requiring urgent transplant.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"98 ","pages":"Article 102444"},"PeriodicalIF":1.6,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148778022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond biopsy and drug levels: Are TTV and dd-CFDNA the next frontiers in transplant monitoring?","authors":"Priya Sharma ,&nbsp;Ankita Ahlawat","doi":"10.1016/j.trim.2026.102393","DOIUrl":"10.1016/j.trim.2026.102393","url":null,"abstract":"<div><div>Emerging biomarkers are reshaping the landscape of post-transplant surveillance by offering non-invasive, biologically meaningful insights beyond traditional biopsy and drug-level monitoring. Torque Teno Virus (TTV), a ubiquitous, non-pathogenic DNA virus, has gained attention as a surrogate marker of the host's net state of immunosuppression. Higher TTV loads correlate with increased immunosuppressive effect and heightened infection risk, while lower levels may reflect under-immunosuppression and potential rejection. Donor-derived cell-free DNA (dd-cfDNA) represents a complementary biomarker of graft integrity, released into the circulation during cellular injury, rejection, or immune-mediated damage. Combined, TTV and dd-cfDNA provide a dual-axis framework that captures both host immune tone and graft injury, offering a more nuanced, personalised approach to post-transplant management. Here, we review the biological basis, current evidence, and clinical applicability of these tools, outlines their limitations, and discusses their potential role in advancing precision immunosuppression in solid-organ transplantation.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"96 ","pages":"Article 102393"},"PeriodicalIF":1.4,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral lung transplantation for severe lung disease caused by a STING1 mutation: A case report","authors":"Yan Lv ,&nbsp;Qi Wang ,&nbsp;Ke Wang ,&nbsp;Yixin Cai ,&nbsp;Meijia Wang ,&nbsp;Zhenli Huang ,&nbsp;Ruijie Zhang ,&nbsp;Junhui Wang ,&nbsp;Suqin Xu ,&nbsp;Huibo Shi ,&nbsp;Huilan Zhang ,&nbsp;Ni Zhang","doi":"10.1016/j.trim.2026.102359","DOIUrl":"10.1016/j.trim.2026.102359","url":null,"abstract":"<div><div>Stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI) is an autoinflammatory syndrome caused by mutations in the stimulator of interferon response cGAMP interactor 1 (<em>STING1</em>) gene, leading to lung and vascular injury. Most patients with SAVI develop disease in childhood or adolescence and rapidly progress to respiratory involvement, primarily interstitial pneumonia (IP) and/or pulmonary interstitial fibrosis (PIF), which may culminate in irreversible end-stage lung disease and respiratory failure. Currently, conventional medical treatments are controversial and challenging, with variable and generally unsatisfactory clinical efficacy. Lung transplantation (LT) remains the most effective strategy to prevent disease progression and improve respiratory function in patients with severe pulmonary involvement. We report in detail the clinical course of a 28-year-old adult patient with SAVI caused by a <em>STING1</em> mutation, with adult-onset disease that rapidly progressed to severe lung injury requiring bilateral LT. Following transplantation, the patient experienced marked improvement of respiratory symptoms, including chest tightness, shortness of breath, and dyspnea, and was able to move freely without ventilator support.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"95 ","pages":"Article 102359"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146132984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accurate prediction of cytomegalovirus disease through optimized viral load cut-offs in intermediate-risk kidney transplant recipients","authors":"Tauana Freitas Casagrande ,&nbsp;Heloisa Cristina Caldas ,&nbsp;Pedro Henrique Fogaça Jordão ,&nbsp;Fernanda Salomão Gorayeb-Polacchini ,&nbsp;Gabriel Ribeiro Ramos ,&nbsp;Ida Maria Maximina Fernandes-Charpiot ,&nbsp;Mario Abbud-Filho","doi":"10.1016/j.trim.2026.102349","DOIUrl":"10.1016/j.trim.2026.102349","url":null,"abstract":"<div><h3>Background</h3><div>Cytomegalovirus (CMV) infection remains a major complication in kidney transplant recipients (KTRs), particularly among donor-negative/recipient-positive (D−/R+) individuals, who are at intermediate risk for viral reactivation. Although CMV DNAemia monitoring allows for preemptive therapy, the optimal threshold to predict disease remains uncertain. This study aimed to determine a clinically relevant CMV DNAemia cut-off for predicting CMV disease in D−/R+ KTRs and evaluate associated clinical outcomes.</div></div><div><h3>Methods</h3><div>A retrospective cohort of 192 D−/R+ KTRs was followed for one year post-transplantation. Patients were stratified by peak CMV DNAemia levels. Clinical, laboratory, and graft-related outcomes were assessed. Logistic regression identified independent predictors of CMV disease. Receiver operating characteristic (ROC) analysis determined the optimal DNAemia threshold.</div></div><div><h3>Results</h3><div>CMV DNAemia ≥1001 IU/mL occurred in 71% of patients and was associated with earlier infection onset, higher peak viral loads, increased use of thymoglobulin, and prolonged delayed graft function (DGF). CMV disease developed in 15% of patients and was independently associated with Kidney Donor Profile Index (KDPI) &gt;80%, elevated DNAemia, longer DGF, lymphopenia, thrombocytopenia, graft loss, and acute rejection. A DNAemia threshold of 14,200 IU/mL (log &gt; 4.15) predicted CMV disease with 63.1% sensitivity and 66.0% specificity (AUC = 0.62). Moreover, recipients of high-KDPI grafts had higher rates of CMV recurrence and peak DNAemia.</div></div><div><h3>Conclusions</h3><div>Elevated CMV DNAemia, poor donor organ quality, and prolonged DGF are key predictors of CMV disease in D−/R+ KTRs. A DNAemia threshold &gt;14,200 IU/mL was associated with an increased risk of CMV disease and may support risk stratification within preemptive management strategies in this intermediate-risk group.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"95 ","pages":"Article 102349"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146006521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Total Leukocyte Chimerism and Lymphocyte Subset Chimerism for Early Detection of Post-Transplant Complications","authors":"Metban Mastanzade ,&nbsp;Figen Abatay Sel ,&nbsp;İpek Yönal Hindilerden ,&nbsp;Yeliz Duvarcı Öğret ,&nbsp;Meliha Nalçacı ,&nbsp;Fatma Savran Oğuz ,&nbsp;Sevgi Kalayoğlu Beşışık","doi":"10.1016/j.trim.2026.102361","DOIUrl":"10.1016/j.trim.2026.102361","url":null,"abstract":"<div><h3>Purpose</h3><div>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with risks of GVHD, graft rejection, and relapse. Chimerism monitoring supports early detection, though the prognostic value of B- and T-cell chimerism remains unclear. We aimed to compare total leukocyte chimerism with lymphocyte subset chimerism to determine their clinical utility in predicting relapse, GVHD, and overall survival (OS) in allo-HSCT recipients.</div></div><div><h3>Methods</h3><div>Patients with hematologic malignancies who underwent allo-HSCT from an HLA-matched sibling or unrelated donor were included. Total leukocyte, B-cell, and T-cell chimerism were analyzed on days 28 and 90 post-transplant. DNA was isolated using a DTAB/CTAB-based method, and chimerism was determined via STR-PCR and capillary electrophoresis. Associations with relapse, GVHD, and event-free survival (EFS) were evaluated. Statistical analysis was performed using SPSS v21.0, including Fisher's exact test, Mann-Whitney <em>U</em> test, and Kaplan-Meier survival analysis.</div></div><div><h3>Results</h3><div>Among 21 allo-HSCT recipients, full donor chimerism (FDC) was observed in 95.2% and mixed chimerism (MC) in 4.8%. Most patients with acute (52.4%) and chronic GVHD (47.6%), relapse (4.8%), or death (19.0%) had FDC. These patterns were consistent across B, T, and total leukocyte subsets on days 28 and 90. Mean disease-free survival was 8.7 months; OS was 11.3 months. No statistically significant association was found between chimerism type and relapse, GVHD, or survival. EFS also did not differ between FDC and MC.</div></div><div><h3>Conclusions</h3><div>Lineage-specific chimerism analysis may enhance early detection of post-transplant complications and improve monitoring precision. However, its clinical utility requires validation in larger cohorts.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"95 ","pages":"Article 102361"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146166986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gamma delta T cell reconstitution in Acute Lymphoblastic Leukemia patients post allogeneic HSCT predicts clinical outcome and overall survival","authors":"Gauri Mirji ,&nbsp;Sachin Punatar ,&nbsp;Navin Khattry ,&nbsp;Shubhada Chiplunkar","doi":"10.1016/j.trim.2026.102358","DOIUrl":"10.1016/j.trim.2026.102358","url":null,"abstract":"<div><div>Predicting the transplant outcome of Acute Lymphoblastic Leukemia patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a challenge. It is necessary to have prognostic biomarkers that can be monitored in these patients. In the present single center, long term follow-up study, immune cell composition or the immunophenotype of Acute Lymphoblastic Leukemia patients (<em>n</em> = 14) was analyzed at various intervals following allogeneic HSCT and correlated with clinical outcomes. Long-term survivors post-HSCT showed distinct immune cell profiles compared to non-survivors. Long term survivors exhibited higher expression of Vδ2⁺CD69⁺ (<em>p</em> = 0.0126), and Vδ1⁺CD16b⁺ T cells (<em>p</em> = 0.0485) at baseline, compared to non-survivors. The analysis of donor immune cell composition showed difference at baseline, donors with higher levels of NKT⁺ cells and lower Vδ1⁺perforin⁺ T cells led to longer survival of respective recipients. Earlier WBC engraftment and incidence of chronic GVHD were other independent clinical factors associated with higher overall survival post- allogeneic HSCT. Furthermore, donors with higher baseline percentages of γδ T cells, CD19⁺ B cells, CD4 T cells, Vδ2 Naïve, Vδ2 TemRA, CD3⁺CD25⁺, and Vδ2⁺CD25⁺; and low Effector Memory CD3⁺ and Vδ1⁺ T cells were associated with fewer Cytomegalovirus (CMV) reactivation in their recipients. The present study underscores the importance of compositional analysis of immune cells in both recipients and donors as a discerning predictive tool for anticipating long-term clinical outcomes following allogeneic HSCT and highlights the need for future validation in larger cohorts.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"95 ","pages":"Article 102358"},"PeriodicalIF":1.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}